BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

Hunting Dark Genes For Druggable Targets

by Tudor Oprea, MD, PhD  (contributor )   •   July 25, 2019  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   Biopharma insight    # Tools & Methods   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email   |  

About one in three human proteins is understudied. Even when quantifying data is available from multiple sources, "dark" genes and proteins are simply not well characterized (Figure 1).

There may be multiple reasons why dark genes are ignored, although the literature isn't always in agreement with data availability.

Are you curious where dark gene hunting leads? There are a number of resources:

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning
  • The Illuminating the Druggable Genome Consortium
  • ... the related Pharos portal
  • ... our collection of drugs, targets and medical applications, DrugCentral
  • ... and the associated NIH Common Fund IDG webpage (with links to past and current funding opportunities)
  • The OpenTargets partnership
  • ... the related OpenTargets Portal
  • The Monarch Initiative
  • The International Mouse Phenotype Consortium
  • The Harmonizome and ChEA3

The development of pharmacological tools to probe the human proteome by 2035 is on its way. And some dark genes could play a role in precision medicine as well, along with other techniques. Of course, what makes a good drug target remains a matter of perspective.

To paraphrase Bengt Åblad, who led the discovery of metoprolol and felodipine (among other drugs), Go find a new drug target today!

Figure 1: SimpleDAS (simple data availability score) counts the association between a protein and 18 data types: publications and patents, gene and protein expression data, availability of 3D structures from X-ray, mouse phenotype associations and GWAS, protein-disease information as well as chemical bioactivity and drug data. Adapted from prior work.

Topics: Tools & Methods   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

You may also be interested to read:

How AI Is Applied To Metabolomics To Identify New Targets And Drugs
by Andrii Buvailo
36 Web Resources For Target Hunting In Drug Discovery
by Alfred Ajami, Andrii Buvailo
How Many Drug Targets Are There? A Status Update Review
by Alfred Ajami
Unveiling Hidden Drug Targets
by Andrii Buvailo

 

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.